Gilead price target lowered to $90 from $101 at Mizuho

Mizuho lowered the firm’s price target on Gilead to $90 from $101 and keeps a Buy rating on the shares. The stock now at a one-year low, nearing the $70-level again, which is historically where investors seem to re-engage a bit more with the story, the analyst tells investors in a research note. The firm continues to believe lenacapivir in pre-exposure prophylaxis could be the next leg of growth investors have been looking for in the stock.